Hopp til hovedinnhold

NSAIDs

NSAIDs utgjør en stor gruppe legemidler med relativt lik betennelsesdempende virkning. Ulempen er at midlene kan forårsake mageplager, i noen tilfeller mageblødninger.

Sist revidert:

QR
Del pasientinformasjon

Den ligger åpent tilgjengelig på NHI.no sammen annen relevant informasjon

https://nhi.no/sykdommer/muskelskjelett/legemiddel/nsaids/ 

Hva er NSAIDs?

Effekt og virkemåte av NSAIDs

Anti-inflammatorisk effekt

Smertestillende effekt

Febernedsettende effekt

Tilstander som kan behandles med NSAIDs

Hvordan NSAIDs brukes

Hvem bør ikke bruke NSAIDs?

Mulige bivirkninger

Vil du vite mer?

Kilder

Referanser

Dette dokumentet er basert på det profesjonelle dokumentet M01A NSAIDs. Referanselisten for dette dokumentet vises nedenfor.

  1. Reikvam Å, Hexeberg S, Kvien TK, et al. Klinisk bruk av COX-hemmere - en konsensus. Tidsskr Nor Lægeforen 2006; 126: 591-5. PubMed 
  2. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332: 1302-8. British Medical Journal 
  3. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase. A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296: 1633-44. Journal of the American Medical Association 
  4. Schmidt M, Sørensen HT, Pedersen L. Diclofenac use and cardiovascular risks: series of nationwide cohort studies. BMJ 2018; 362: k3426. doi:10.1136/bmj.k3426 DOI 
  5. Bally M, Dendukuri N, Rich B, et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data.. BMJ 2017. pmid:28487435 PubMed 
  6. Schjerning Olsen A, Fosbøl L, Lindhardsen J, et al. Long-term cardiovascular risk of NSAID use according to time passed after first-time myocardial infarction. A nationwide cohort study. Circulation 2012. doi:10.1161/​CIRCULATIONAHA.112.112607.
  7. Laine L, White WB, Rostom A, Hochberg M. COX-2 Selective inhibitors in the treatment of osteoarthritis. Semin Arthritis Rheum 2008; Epub ahead of print.
  8. Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med 2016 Dec; 375(26): 2519-29. pmid:27959716 PubMed 
  9. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365: 475-81. PubMed 
  10. Vaile JH, Davis P. Topical NSAIDs for musculoskeletal conditions. A review of the literature. Drugs 1998; 56: 783-99. PubMed 
  11. Moore RA, Tramer MR, Carroll D, Wiffen PJ, McQuay HJ. Quantitative systematic review of topically applied non-steroidal anti-inflammatory drugs. BMJ 1998; 316: 333-8. PubMed 
  12. Lin J, Zhang W, Jones A, Doherty M. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. BMJ 2004; 329: 324-6. PubMed 
  13. Derry S, Conaghan P, Da Silva JA. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev 2016 Apr; 4: CD007400. pmid:27103611 PubMed 
  14. Deng ZH, Zeng C, Yang Y, et al. Topical diclofenac therapy for osteoarthritis: a meta-analysis of randomized controlled trials. Clin Rheumatol 2016 May; 35(5): 1253-61. pmid:26242469 PubMed 
  15. Gøtzsche P. Non-steroidal anti-inflammatory drugs. Clin Evid 2001; 6: 894-901. Clinical Evidence 
  16. Gøtzsche P. Meta-analysis of NSAIDs: contribution of drugs, doses, trial designs, and meta-analytic techniques. Scand J Rheumatol 1993; 22: 255-60. PubMed 
  17. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. JAMA 1999; 282: 1921-8. Journal of the American Medical Association 
  18. Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 2004; 329: 948. British Medical Journal 
  19. Scarpignato C, Gatta L, Zullo A, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med 2016 Nov; 14(1): 179. pmid:27825371 PubMed 
  20. RELIS: Diklofenak til korttidsbruk og kardiovaskulær sykdom relis.no 
  21. Legeforeningen. Gjør kloke valg. Anbefalinger. Siden besøkt 11.02.2021 www.legeforeningen.no 
  22. Risser A, Donovan D, Heintzman J, Page T. NSAID prescribing precautions. Am Fam Physician 2009; 80: 1371-8. American Family Physician 
  23. Rugstad HE, Giercksky K-E, Husby G, Holme I. Effect of cimetidine on gastrointestinal symptoms in patients taking nonsteroidal anti-inflammatory drugs. Scand J Rheumatol 1994; 23: 177-82. PubMed 
  24. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Sted H et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999; 354: 2106-11. PubMed 
  25. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, McGowan J. Prevention of NSAID-induced gastroduodenal ulcers (Cochrane Review). In: The Cochrane Library, Issue 4, 2002. The Cochrane Library 
  26. Slørdal L, Spigset O. Hypertensjon og hjertesvikt forårsaket av NSAID-preparater. Tidsskr Nor Lægeforen 2000; 120: 2904-5. Tidsskrift for Den norske legeforening 
  27. Skomsvoll JF, Rødevand E, Koksvik HS, et al. Reversibel infertilitet ved ikke-steroide antiinflammatoriske midler. Tidsskr Nor Lægeforen 2005; 125: 1476-8. PubMed 
  28. Os I. COX-2-hemmere og effekt på nyrer og blodtrykk. Tidsskr Nor Lægeforen 2003; 123: 1339-41. PubMed 
  29. Nielsen GL, Sørensen HT, Larsen H, Pedersen L. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study. BMJ 2001; 322: 266-70. PubMed 
  30. Nakhai-Pour HR, Broy P, Sheehy O, Bérard A. Use of nonaspirin non-steroidal antiinflammatory drugs during pregnancy and the risk of spontaneous abortion . CMAJ 2011; 183: 1713-20. Canadian Medical Association Journal 
  31. Daniel S, Koren G, Lunenfeld E, et al. Fetal exposure to nonsteroidal anti-inflammatory drugs and spontaneous abortions. CMAJ. 2014;186:E177-82. PMID: 24491470 PubMed 
  32. Daniel S, Matok I, Gorodischer R, et al. Major malformations following exposure to nonsteroidal antiinflammatory drugs during the first trimester of pregnancy. J Rheumatol 2012; 39: 2163-9. PubMed 
  33. Statens legemiddelverk. Nytt om legemidler no 5; 2014.
  34. Cerezo JG, Hristov RL, Carcas Sansuán AJ, Vázquez Rodríguez JJ. Outcome trials of COX-2 selective inhibitors: global safety evaluation does not promise benefits. Eur J Clin Pharm 2003; 59: 169-175. PubMed 
  35. Evensen S, Spigset O, Slørdal L. COX-2-hemmere - ett skritt frem og to tilbake. Tidsskr Nor Lægeforen 2005; 125: 875-8. PubMed 
  36. Updated advice on use of high-dose ibuprofen. European Medicines Agency. Press releaase 22.05.2015
  37. Coxib and traditional NSAIDs Trialists Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analysis of individual participant data from randomised trials. Lancet 2013; May 29 doi:pii: S0140-6736(13)60900-9. 10.1016/S0140-6736(13)60900-9.Epub ahead of print
  38. Borregaard Larsen J, Thirstrup Pedersen S. Nonsteroide antiinflammatoriske stoffer - mulige risici ved anvendelse under graviditet. Ugeskr Læger 2006; 168: 3709-11. PubMed 
  39. Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013; 382: 769-779. PubMed 
  40. Helin-Salmivaara A, Virtanen A, Vesalainen R, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 2006; 27: 1657-63. European Heart Journal